Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: "Eric L Matteson" Clear advanced filters

  • Polymyalgia rheumatica (PMR) is an inflammatory disorder of unknown aetiology that can be extremely disabling when active. Glucocorticoids are currently the therapy of choice for patients with PMR, but responsiveness to treatment varies considerably. The identification of different morphological patterns of disease defined by distinct extracapsular or capsular-based inflammation might, at least in part, explain this variability in responses to treatment.

    • Frank Buttgereit
    • Eric L. Matteson
    News & Views
    Nature Reviews Rheumatology
    Volume: 12, P: 140-141

  • Polymyalgia rheumatica is widely acknowledged as the most common form of inflammatory rheumatic disease in the elderly. Two recent studies by Hernandez-Rodriguez et al. and Dasgupta et al. attempt to synthesize and pragmatize recommendations for the evaluation and treatment of this disorder.

    • Eric L. Matteson
    News & Views
    Nature Reviews Rheumatology
    Volume: 6, P: 249-250

  • The degree to which the elevated risk of malignant lymphomas in patients with rheumatoid arthritis (RA) is related to disease activity or to therapy is uncertain. Evidence is mounting in support of a strategy of more-intensive cancer screening in these patients.

    • Eric L. Matteson
    News & Views
    Nature Reviews Rheumatology
    Volume: 5, P: 474-475

  • Concerns have been raised over an association between biologic agents used in the treatment of rheumatoid arthritis (RA) and noninfectious serious respiratory adverse events, particular in patients with pre-existing RA-associated interstitial lung disease (RA-ILD). In this Review, the current evidence regarding the comparative pulmonary safety of the available biologic therapies is discussed and a framework to guide treatment decisions is provided. The authors also identify the considerable gaps in our understanding of the associations between biologic agents and RA-ILD, and propose a research agenda aimed at addressing them.

    • Meghna Jani
    • Nik Hirani
    • William G. Dixon
    Reviews
    Nature Reviews Rheumatology
    Volume: 10, P: 284-294

  • Rapid progress in the fields of giant cell arteritis and polymyalgia rheumatica has resulted in the introduction of imaging techniques into routine clinical practice and in promising reports on the efficacy of biologic agents for treatment. Further research should further advance our understanding of the epidemiology, pathogenesis, imaging and treatment of these diseases.

    • Christian Dejaco
    • Elisabeth Brouwer
    • Bhaskar Dasgupta
    Reviews
    Nature Reviews Rheumatology
    Volume: 13, P: 578-592